CO6630127A2 - Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar - Google Patents
Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliarInfo
- Publication number
- CO6630127A2 CO6630127A2 CO12171902A CO12171902A CO6630127A2 CO 6630127 A2 CO6630127 A2 CO 6630127A2 CO 12171902 A CO12171902 A CO 12171902A CO 12171902 A CO12171902 A CO 12171902A CO 6630127 A2 CO6630127 A2 CO 6630127A2
- Authority
- CO
- Colombia
- Prior art keywords
- virus
- particle
- auxiliary
- beta
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones que comprenden una construcción que comprende el péptido Aß1-6 y un auxiliar farmacéuticamente aceptable, para el tratamiento de pacientes que sufren de demencia, en particular demencia del tipo Alzheimer. En una modalidad, la construcción que contiene el péptido Aß1 -6 consiste de una partícula similar a virus (VLP) del bacteriófago de RNA Qß químicamente acoplado a dicho péptido Aß1 -6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10158273 | 2010-03-29 | ||
US36169710P | 2010-07-06 | 2010-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6630127A2 true CO6630127A2 (es) | 2013-03-01 |
Family
ID=42285305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12171902A CO6630127A2 (es) | 2010-03-29 | 2012-10-01 | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar |
Country Status (23)
Country | Link |
---|---|
US (4) | US20130011431A1 (es) |
EP (1) | EP2552489A1 (es) |
JP (2) | JP6088422B2 (es) |
KR (1) | KR20130018407A (es) |
CN (2) | CN104436212A (es) |
AR (1) | AR080810A1 (es) |
AU (1) | AU2011234656B2 (es) |
BR (1) | BR112012024708A2 (es) |
CA (1) | CA2793580A1 (es) |
CL (1) | CL2012002685A1 (es) |
CO (1) | CO6630127A2 (es) |
EC (1) | ECSP12012180A (es) |
GT (1) | GT201200265A (es) |
IL (1) | IL221540B (es) |
MA (1) | MA34084B1 (es) |
MX (1) | MX2012011340A (es) |
NZ (1) | NZ601729A (es) |
PE (1) | PE20130642A1 (es) |
RU (1) | RU2603486C2 (es) |
SG (2) | SG183806A1 (es) |
TN (1) | TN2012000431A1 (es) |
TW (2) | TW201138805A (es) |
WO (1) | WO2011120924A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10195257B2 (en) | 2013-07-28 | 2019-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response |
WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
WO2015165974A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of dementias associated with amyloid deposition, preferably alzheimer's disease (ad) |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
EP3269376B1 (en) | 2014-04-29 | 2020-07-15 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
EP3137094B1 (en) * | 2014-04-29 | 2022-12-07 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
AU8298298A (en) * | 1997-07-08 | 1999-02-08 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
CN100350972C (zh) * | 2001-07-26 | 2007-11-28 | 启龙股份公司 | 含有铝佐剂和组氨酸的疫苗 |
RU2450827C2 (ru) * | 2002-07-19 | 2012-05-20 | Цитос Биотехнологи Аг | Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6 |
CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
CA2580208A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 EP EP11711322A patent/EP2552489A1/en not_active Withdrawn
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Application Discontinuation
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/en active Application Filing
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 CA CA2793580A patent/CA2793580A1/en not_active Abandoned
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2011234656B2 (en) | 2013-08-01 |
ECSP12012180A (es) | 2012-10-30 |
US20140348871A1 (en) | 2014-11-27 |
CL2012002685A1 (es) | 2013-01-25 |
MX2012011340A (es) | 2012-11-16 |
TW201138805A (en) | 2011-11-16 |
US20150297692A1 (en) | 2015-10-22 |
KR20130018407A (ko) | 2013-02-21 |
TN2012000431A1 (en) | 2014-01-30 |
AR080810A1 (es) | 2012-05-09 |
MA34084B1 (fr) | 2013-03-05 |
RU2603486C2 (ru) | 2016-11-27 |
TW201618806A (zh) | 2016-06-01 |
CA2793580A1 (en) | 2011-10-06 |
JP2017008035A (ja) | 2017-01-12 |
WO2011120924A1 (en) | 2011-10-06 |
SG10201505374TA (en) | 2015-08-28 |
BR112012024708A2 (pt) | 2016-06-07 |
IL221540B (en) | 2018-11-29 |
CN102834118A (zh) | 2012-12-19 |
GT201200265A (es) | 2014-03-14 |
JP2013523682A (ja) | 2013-06-17 |
US20160101167A1 (en) | 2016-04-14 |
EP2552489A1 (en) | 2013-02-06 |
JP6088422B2 (ja) | 2017-03-01 |
CN104436212A (zh) | 2015-03-25 |
AU2011234656A1 (en) | 2012-10-11 |
PE20130642A1 (es) | 2013-06-19 |
RU2012145734A (ru) | 2014-05-10 |
SG183806A1 (en) | 2012-10-30 |
US20130011431A1 (en) | 2013-01-10 |
NZ601729A (en) | 2013-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6630127A2 (es) | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar | |
AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
NI201100145A (es) | Composición farmacéutica sólida que comprende amlodipina y losartan con estabilidad mejorada. | |
CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
CL2009000915A1 (es) | Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd). | |
CO6430422A2 (es) | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1, 3-diona | |
WO2012050918A3 (en) | Tricyclic fused ring inhibitors of hepatitis c | |
HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
CU20180035A7 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
MY164842A (en) | Isoxazolidine derivatives | |
CL2014000394A1 (es) | Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos. | |
CL2014000552A1 (es) | Uso de 4,4´-[fluoro-(1h-1,2,4-triazol-1-il)metileno]bisbenzonitrilo para el tratamiento del hipogonadismo y composicion farmaceutica oral que comprende al compuesto y kit farmaceutico que comprende a la composicion. | |
NI201200144A (es) | Anticuerpos humanizados de il - 25 | |
CL2019002133A1 (es) | Partícula similar a virus (vlp). | |
CL2015000848A1 (es) | Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12). | |
MY194140A (en) | Isoxazolidine derivatives | |
CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
WO2013024494A3 (en) | Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone | |
PH12015500534B1 (en) | Isoxazolidine derivatives | |
WO2012123493A9 (en) | Isoxazolidine derivatives | |
ES2403130R1 (es) | Forma polimorfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparacion | |
BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
CR20140273A (es) | Composiciones y métodos para tratar el virus de la hepatitis c |